Ser291
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser291  -  osteopontin (human)

Site Information
MLVVDPKsKEEDKHL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455725

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 , 4 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , milk ( 3 , 4 ) , urine ( 3 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Li H, et al. (2015) Site-specific structural characterization of O-glycosylation and identification of phosphorylation sites of recombinant osteopontin. Biochim Biophys Acta 1854, 581-91
25450502   Curated Info

3

Christensen B, Petersen TE, Sørensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411, 53-61
18072945   Curated Info

4

Christensen B, et al. (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390, 285-92
15869464   Curated Info